Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10446927rdf:typepubmed:Citationlld:pubmed
pubmed-article:10446927lifeskim:mentionsumls-concept:C0001483lld:lifeskim
pubmed-article:10446927lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:10446927lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:10446927lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:10446927lifeskim:mentionsumls-concept:C1160185lld:lifeskim
pubmed-article:10446927lifeskim:mentionsumls-concept:C0439855lld:lifeskim
pubmed-article:10446927pubmed:issue11lld:pubmed
pubmed-article:10446927pubmed:dateCreated1999-10-28lld:pubmed
pubmed-article:10446927pubmed:abstractTextWe have evaluated, as a vector for gene transfer into human T lymphocytes, a recombinant adenovirus (rAd-MFG-AP) carrying a modified, membrane-exposed, alkaline phosphatase (AP) as reporter gene. CD3+ cells were selected from the buffy coat of healthy donors by the immunomagnetic technique. The positive cell population, comprising 96+/-2% CD3+ cells, was cultured with clinical-grade cytokine(s) for 3-7 days prior to rAd-MFG-AP transduction and the transgene expression was evaluated 48 hr later by indirect immunofluorescence flow cytometry assay with an anti-alkaline phosphatase antibody. The best efficiency of transduction was achieved on incubation of CD3+ cells with IL-2 plus either IL-12 (AP+ cells, 12+/-3%) or IL-7 (AP+ cells, 11+/-3%). To increase further the efficiency of transduction, we have combined LipofectAMINE and rAd-MFG-AP with the aim to enhance the uptake of viral particles into the target cells. The percentage of CD3+ cells transduced by rAd-MFG-AP-LipofectAMINE complex was 24+/-4% (range, 20-35%) after incubation with IL-2 plus IL-7 and 22+/-4% (range, 18-32%) after incubation with II-2 plus IL-12. Forty-eight hours after the incubation with rAd-MFG-AP, the transduced T lymphocytes were subjected to fluorescence-activated cell sorting and fractionated into AP+ and AP- cell subpopulations. The AP+ cell fraction, comprising 96.8% of AP+ cells, was evaluated by FACScan analysis for T lymphocyte surface antigens. The immunophenotyping of the transduced T lymphocytes has shown that there was not a particular subtype of T lymphocytes more susceptible to rAd-MFG-AP transduction. In addition, the transgene expression did not modify T lymphocyte functions, as demonstrated by results obtained by cytotoxicity assay before and after rAd-MFG-AP-LipofectAMINE complex transduction. In conclusion, human T lymphocytes can be efficiently transduced, under clinically applicable conditions, by adenovirus-LipofectAMINE complex after 7 days of culture with IL-2 and IL-12 or IL-7.lld:pubmed
pubmed-article:10446927pubmed:languageenglld:pubmed
pubmed-article:10446927pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10446927pubmed:citationSubsetIMlld:pubmed
pubmed-article:10446927pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10446927pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10446927pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10446927pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10446927pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10446927pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10446927pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10446927pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10446927pubmed:statusMEDLINElld:pubmed
pubmed-article:10446927pubmed:monthJullld:pubmed
pubmed-article:10446927pubmed:issn1043-0342lld:pubmed
pubmed-article:10446927pubmed:authorpubmed-author:JordanCClld:pubmed
pubmed-article:10446927pubmed:authorpubmed-author:GianniA MAMlld:pubmed
pubmed-article:10446927pubmed:authorpubmed-author:MagniMMlld:pubmed
pubmed-article:10446927pubmed:authorpubmed-author:BregniMMlld:pubmed
pubmed-article:10446927pubmed:authorpubmed-author:Di NicolaMMlld:pubmed
pubmed-article:10446927pubmed:authorpubmed-author:ScarpaMMlld:pubmed
pubmed-article:10446927pubmed:authorpubmed-author:TomaninRRlld:pubmed
pubmed-article:10446927pubmed:authorpubmed-author:Carlo-StellaC...lld:pubmed
pubmed-article:10446927pubmed:authorpubmed-author:LongoniPPlld:pubmed
pubmed-article:10446927pubmed:authorpubmed-author:RavagnaniFFlld:pubmed
pubmed-article:10446927pubmed:authorpubmed-author:MilanesiMMlld:pubmed
pubmed-article:10446927pubmed:issnTypePrintlld:pubmed
pubmed-article:10446927pubmed:day20lld:pubmed
pubmed-article:10446927pubmed:volume10lld:pubmed
pubmed-article:10446927pubmed:ownerNLMlld:pubmed
pubmed-article:10446927pubmed:authorsCompleteYlld:pubmed
pubmed-article:10446927pubmed:pagination1875-84lld:pubmed
pubmed-article:10446927pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:meshHeadingpubmed-meshheading:10446927...lld:pubmed
pubmed-article:10446927pubmed:year1999lld:pubmed
pubmed-article:10446927pubmed:articleTitleRecombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes.lld:pubmed
pubmed-article:10446927pubmed:affiliationDivision of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy. dinicola@istitutotumori.mi.itlld:pubmed
pubmed-article:10446927pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10446927pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10446927lld:pubmed